CYTOKINETICS INC

Cytokinetics announced that three Late Breaking Science abstracts, including primary results from the ACACIA-HCM Phase 3 clinical trial of aficamten in non-obstructive hypertrophic cardiomyopathy (HCM), have been accepted for presentation at the European Society of Cardiology (ESC) Congress. The Hot Line presentation of the positive topline results is scheduled for August 28, 2026. The company will also host an investor event to discuss these results.

Cytokinetics announced the first commercial European launch of MYQORZO (aficamten) in Germany for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in adult patients. This follows the European Commission approval in February 2026, which was based on positive results from the pivotal Phase 3 SEQUOIA-HCM clinical trial. MYQORZO was previously approved in December 2025 by the U.S. FDA and the China National Medical Products Administration (NMPA), marking a significant global expansion for the company's cardiac myosin inhibitor.

Cytokinetics, Incorporated announced that its management team will participate in two upcoming investor conferences in June. These include a fireside chat at the 2026 Jefferies Global Healthcare Conference on June 3, 2026, and another at the Goldman Sachs 47th Annual Global Healthcare Conference on June 8, 2026. Live webcasts and replays will be available on the company's investor relations website. Cytokinetics is a cardiovascular biopharmaceutical company with an approved product, MYQORZO (aficamten), and a pipeline of investigational medicines.

Cytokinetics, Incorporated announced its Annual Meeting of Stockholders will be held on Wednesday, May 27, 2026, at 10:00 AM Pacific Time at its headquarters. Stockholders of record as of March 31, 2026, are eligible to vote, with proxy submissions due by May 26, 2026. Following the meeting, President and CEO Robert I. Blum will provide an overview of the company's performance. A live webcast and archived replay will be available for interested parties.

Cytokinetics announced it granted equity awards to 8 new employees who commenced employment in April and May 2026. These awards include stock options to purchase 20,807 shares of common stock and 13,793 restricted stock units (RSUs). The grants serve as a material inducement for their employment, aligning with Nasdaq listing rules.

Cytokinetics announced that its management team will participate in a fireside chat at the 2026 RBC Capital Markets Global Healthcare Conference. The event is scheduled for May 19, 2026, at 3:35 PM ET in New York, NY, with a live webcast and 90-day replay available on the company's investor relations website. Cytokinetics is a biopharmaceutical company specializing in cardiovascular diseases, with its approved drug MYQORZO (aficamten) for obstructive hypertrophic cardiomyopathy and other investigational medicines in its pipeline.

Cytokinetics announced new data from SEQUOIA-HCM, MAPLE-HCM, and FOREST-HCM trials, reinforcing MYQORZO's clinical profile and long-term safety at the ESC Heart Failure 2026 Congress. The analyses showed MYQORZO outperformed metoprolol across sex and doses, demonstrated long-term safety without increased arrhythmia incidence, and positively affected left atrium remodeling. Additionally, real-world evidence highlighted the significant burden of hypertrophic cardiomyopathy (HCM) and the unmet need for effective therapies.

Cytokinetics, Incorporated completed a public offering of its common stock, raising approximately $760.2 million in net proceeds. The company initially offered 9,859,155 shares at $71.00 per share. The underwriters fully exercised their option to purchase an additional 1,478,873 shares, bringing the total shares sold to 11,338,028.

Cytokinetics, Incorporated announced the closing of its underwritten public offering of common stock, generating approximately $805 million in gross proceeds. The company sold a total of 11,338,028 shares, including the full exercise of the underwriters' option, at a price of $71.00 per share. This capital raise was conducted pursuant to a shelf registration statement.

Cytokinetics, Incorporated announced the pricing of an underwritten public offering of 9,859,155 shares of its common stock at $71.00 per share. The offering is expected to generate approximately $700 million in gross proceeds for the company, before deducting underwriting discounts and other expenses. The offering is anticipated to close on May 8, 2026, and includes a 30-day option for underwriters to purchase up to an additional 1,478,873 shares.